文献速递生殖医学

微粒化黄体酮联合地屈孕酮与单用微粒化黄体酮在冻融胚胎周期黄体支持中的比较(MIDRONE):前瞻性队列研究

Micronized progesterone plus dydrogesterone versus micronized progesterone alone for luteal phase support in frozen-thawed cycles (MIDRONE): a prospective cohort study.
PubMed 文献 · Hum Reprod · 2021-01-01

该前瞻性队列研究在越南一家学术不孕中心纳入1364例接受冻融胚胎移植的IVF女性,比较阴道微粒化黄体酮联合口服地屈孕酮与单用阴道微粒化黄体酮进行黄体支持的效果。联合组活产率46.3% vs 41.3%(RR 1.12,95%CI 0.99-1.27,P=0.06;多因素分析RR 1.30,95%CI 1.01-1.68,P=0.042),<12周流产率显著降低(3.4% vs 6.6%,RR 0.51,95%CI 0.32-0.83,P=0.009)。

要点

  • 联合地屈孕酮组<12周流产率显著低于单用组(3.4% vs 6.6%,P=0.009)。
  • 多因素分析中联合组活产率显著提高(RR 1.30,95%CI 1.01-1.68,P=0.042)。
  • 联合组单胎和双胎出生体重均显著低于单用组。

核心结论

  • 在冻融胚胎移植周期中,阴道微粒化黄体酮联合口服地屈孕酮进行黄体支持较单用阴道微粒化黄体酮可降低<12周流产率并可能提高活产率。

研究设计与样本

  • 前瞻性队列研究,2019年6月26日至2020年3月30日在越南一家学术不孕中心开展,共纳入1364例接受IVF冻融胚胎移植的女性。
  • 黄体支持方案为阴道微粒化黄体酮400mg每日两次联合口服地屈孕酮10mg每日两次(研究后半段)或单用阴道微粒化黄体酮400mg每日两次(研究前4个月)。
  • 主要终点为启动周期首次冻融胚胎移植后的活产,<12周流产为次要终点之一。

主要发现

  • 联合组732例,单用组632例;活产率分别为46.3%和41.3%(RR 1.12,95%CI 0.99-1.27,P=0.06;多因素分析RR 1.30,95%CI 1.01-1.68,P=0.042)。
  • 联合组<12周流产率显著低于单用组(3.4% vs 6.6%;RR 0.51,95%CI 0.32-0.83;P=0.009)。
  • 联合组单胎出生体重显著低于单用组(2971.0±628.4 g vs 3118.8±559.2 g;P=0.004)。
  • 联合组双胎出生体重显著低于单用组(2175.5±494.8 g vs 2494.2±584.7 g;P=0.002)。

临床怎么用

  • 对于冻融胚胎移植周期,可考虑在阴道微粒化黄体酮基础上加用口服地屈孕酮以降低早期流产率并可能改善活产率。
  • 需注意联合方案可能与单胎和双胎出生体重降低相关,应个体化评估。

局限性

  • 研究为开放标签设计,且两种治疗按时间顺序先后实施,非随机分组。
  • 单一人种人群限制了外部推广性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Does the addition of oral dydrogesterone to vaginal progesterone as luteal phase support improve pregnancy outcomes during frozen embryo transfer (FET) cycles compared with vaginal progesterone alone? SUMMARY ANSWER: Luteal phase support with oral dydrogesterone added to vaginal progesterone had a higher live birth rate and lower miscarriage rate compared with vaginal progesterone alone. WHAT IS KNOWN ALREADY: Progesterone is an important hormone that triggers secretory transformation of the endometrium to allow implantation of the embryo. During IVF, exogenous progesterone is administered for luteal phase support. However, there is wide inter-individual variation in absorption of progesterone via the vaginal wall. Oral dydrogesterone is effective and well tolerated when used to provide luteal phase support after fresh embryo transfer. However, there are currently no data on the effectiveness of luteal phase support with the combination of dydrogesterone with vaginal micronized progesterone compared with vaginal micronized progesterone after FET. STUDY DESIGN, SIZE, DURATION: Prospective cohort study conducted at an academic infertility center in Vietnam from 26 June 2019 to 30 March 2020. PARTICIPANTS/MATERIALS, SETTING, METHODS: We studied 1364 women undergoing IVF with FET. Luteal support was started when endometrial thickness reached ≥8 mm. The luteal support regimen was either vaginal micronized progesterone 400 mg twice daily plus oral dydrogesterone 10 mg twice daily (second part of the study) or vaginal micronized progesterone 400 mg twice daily (first 4 months of the study). In women with a positive pregnancy test, the appropriate luteal phase support regimen was continued until 7 weeks' gestation. The primary endpoint was live birth after the first FET of the started cycle, with miscarriage <12 weeks as one of the secondary endpoints. MAIN RESULTS AND THE ROLE OF CHANCE: The vaginal progesterone + dydrogesterone group and vaginal progesterone groups included 732 and 632 participants, respectively. Live birth rates were 46.3% versus 41.3%, respectively (rate ratio [RR] 1.12, 95% CI 0.99-1.27, P = 0.06; multivariate analysis RR 1.30 (95% CI 1.01-1.68), P = 0.042), with a statistically significant lower rate of miscarriage at <12 weeks in the progesterone + dydrogesterone versus progesterone group (3.4% versus 6.6%; RR 0.51, 95% CI 0.32-0.83; P = 0.009). Birth weight of both singletons (2971.0 ± 628.4 versus 3118.8 ± 559.2 g; P = 0.004) and twins (2175.5 ± 494.8 versus 2494.2 ± 584.7; P = 0.002) was significantly lower in the progesterone plus dydrogesterone versus progesterone group. LIMITATIONS, REASONS FOR CAUTION: The main limitations of the study were the open-label design and the non-randomized nature of the sequential administration of study treatments. However, our systematic comparison of the two strategies was able to be performed much more rapidly than a conventional randomized controlled trial. In addition, the single ethnicity population limits external generalizability. WIDER IMPLICATIONS OF THE FINDINGS: Our findings study suggest a role for oral dydrogesterone in addition to vaginal progesterone as luteal phase support in FET cycles to reduce the miscarriage rate and improve the live birth rate. Carefully planned prospective cohort studies with limited bias could be used as an alternative to randomized controlled clinical trials to inform clinical practice. STUDY FUNDING/COMPETING INTERESTS: This study received no external funding. LNV has received speaker and conference fees from Merck, grant, speaker and conference fees from Merck Sharpe and Dohme, and speaker, conference and scientific board fees from Ferring; TMH has received speaker fees from Merck, Merck Sharp and Dohme, and Ferring; R.J.N. has received scientific board fees from Ferring and receives grant funding from the National Health and Medical Research Council (NHMRC) of Australia; BWM has acted as a paid consultant to Merck, ObsEva and Guerbet, and is the recipient of grant money from an NHMRC Investigator Grant. TRIAL REGISTRATION NUMBER: NCT0399876.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Vuong LN, Pham TD, Le KTQ, et al. Micronized progesterone plus dydrogesterone versus micronized progesterone alone for luteal phase support in frozen-thawed cycles (MIDRONE): a prospective cohort study. Hum Reprod. 2021. PMID: 33930124. doi:10.1093/humrep/deab093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。